Natera (NASDAQ:NTRA) Releases Quarterly Earnings Results

Natera (NASDAQ:NTRA) posted its quarterly earnings data on Thursday. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01, Zacks reports. The business had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera updated its FY 2025 guidance to EPS.

Natera Stock Performance

Shares of NTRA opened at $155.59 on Friday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera has a 52-week low of $83.13 and a 52-week high of $183.00. The company has a 50-day simple moving average of $167.44 and a 200-day simple moving average of $146.95. The company has a market capitalization of $20.54 billion, a PE ratio of -88.40 and a beta of 1.66.

Insider Buying and Selling

In other news, Director Roelof Botha sold 87,473 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the sale, the director now owns 1,224,787 shares of the company’s stock, valued at $207,135,977.44. The trade was a 6.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John Fesko sold 663 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the completion of the sale, the insider now owns 156,044 shares in the company, valued at approximately $27,739,941.88. This represents a 0.42 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 295,772 shares of company stock valued at $49,741,699. Corporate insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Morgan Stanley increased their price target on Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Craig Hallum increased their price objective on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Canaccord Genuity Group reiterated a “buy” rating and set a $180.00 target price on shares of Natera in a research report on Wednesday. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Finally, Guggenheim increased their price target on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $172.69.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.